NCT03882684

Role of Genomic Imprinting in Cancer Diagnosis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (estimated)
• Sponsor: Chinese Alliance Against Lung Cancer · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The current research focus for cancer diagonosis is classical genetics, named "driving genes". However, not all cancer patients have typical genetic alterations, especially at early stage. In the past dacades, accumulating evidences have revealed that more than 80% diseases are closely related to epigenetic changes. The normally silenced copy of imprinted genes are reactivated at early stage of cancers, and finally proceed to copy number variation. This study will screen for a panel of imprinted genes and build quantitative models to assist the diagnosis of multiple cancers.

Conditions

• Early Diagnosis
• Cancer
• Biomarker
• Genomic Imprinting

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	In-situ imprinting detection	The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.

Timeline

• Start date: 2017-07-01
• Primary completion: 2019-03-31
• Completion: 2020-06-30
• First posted: 2019-03-20
• Last updated: 2019-03-20

Locations

1 site across 1 country: China